Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus CEPTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus CEPTAZ.
CEFEPIME HYDROCHLORIDE vs CEPTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase and carboxypeptidase activity, leading to cell lysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing cell lysis.
1-2 g IV every 8-12 hours; for uncomplicated urinary tract infections, 500 mg IV every 12 hours.
1 to 2 g intravenously every 8 to 12 hours; maximum 6 g per day.
None Documented
None Documented
2-2.3 hours in healthy adults (prolonged to 13-15 hours in severe renal impairment; requires dosage adjustment).
Approximately 2 hours in patients with normal renal function; prolonged to 3-5 hours in mild-moderate renal impairment and >20 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <1%.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic